Assessing response to treatment using imaging with PET/MRI in advanced renal cancer

Not Applicable

• Conditions: Renal cell carcinoma; Cancer; Malignant neoplasm of kidney, except renal pelvis

• Registration Number: ISRCTN12114913
• Lead Sponsor: King's College London

Brief Summary

2017 Protocol article in https://www.ncbi.nlm.nih.gov/pubmed/28578690 protocol

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-11-16
• Last Update Posted: 5 August 2022
• Study Completion: 2023-02-01

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 38

Inclusion Criteria

1. Adult patients (male or female > 18 years old) with metastatic renal cell carcinoma
2. Metastases with =1 measurable sites, =2cm, planned for targeted therapy
3. ECOG performance status 0-2

Exclusion Criteria

1. Contraindications to contrast-enhanced MRI or CT or FDG PET including renal impairment eGFR <50
2. Estimated prognosis < 12 weeks
3. ECOG performance status > 2
4. Previous radiotherapy

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
disease response or non-response measured by PET/MRI and CT at 12 and 24 weeks and clinical examination and CT at 36 weeks.

Secondary Outcome Measures

Name	Time	Method
Time to progression will be measured by clinical examination and CT at standard three to six monthly follow up clinic visits.